By Elias Schisgall

Shares of Clarivate surged after the company swung to a profit in the fourth quarter and said it was pursuing a sale of its life-sciences & healthcare business.

Shares were up 30% to $2.19 in Tuesday morning trading. The stock has fallen 52% over the past year.

The analytics company said Tuesday that it decided to pursue a sale of the life-sciences & healthcare business following a strategic review of its portfolio. A sale would allow it to focus on its academia & government and intellectual property markets, while strengthening its balance sheet, the company said.

Clarivate posted a fourth-quarter profit of $3.1 million, breakeven on a per-share basis, compared with a loss of $191.8 million, or 27 cents a share, a year earlier.

Stripping out certain one-time items, the company logged adjusted earnings of 20 cents a share. Analysts polled by FactSet were expecting 16 cents a share.

Revenue fell 6.9% to $617 million, down from $663 million a year prior. Much of the dip came from a decline in transactional revenue to $97.1 million from $144 million last year, reflecting divestitures in disposals in the academia & government and life-sciences & healthcare segments, the company said.

Transactional revenue fell about 12% on an organic basis due to lower intellectual-property volumes, Clarivate added.

For the current year, the company said it expects revenue between $2.3 billion and $2.42 billion, with recurring organic revenue expected to grow between 0.75% and 2.25%.

Analysts are expecting $2.38 billion in revenue for the year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

February 24, 2026 11:11 ET (16:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.